

# Science **et** technique

Revue burkinabè de la recherche

## *Sciences naturelles et appliquées*

---

Vol. 39, n° 2 (1) — Juillet-Décembre 2020 — ISSN 1011-6028

---



Centre national de la recherche scientifique et technologique 03 B.P. 7047  
Ouagadougou 03 – Burkina Fas



Revue semestrielle de la recherche  
du **Centre National de la  
Recherche  
Scientifique et Technologique  
(CNRST)**



-----  
**Série Sciences naturelles et Appliquées**

**Volume 39, numéro 2 (1)**

**Juillet-Décembre 2020**

Prix : 3 000 F CFA

**Directeur de publication**

NEBIE Roger Honorat Charles, Délégué général du CNRST

**Directeurs adjoints de publication** : TRAORE Hamidou ;

SAWADOGO/LINGANI Hagrétou

**Comité de publication**

*Président* : YAMEOGO Georges

*Editeur scientifique* : HALPOUGDOU Martial

**Comité de rédaction**

*Coordonnateurs* : Hadja SANON Oumou  
NANEMA Emmanuel

**Rédacteurs en Chef** : YONLI Djibril  
IGO Serges

**Rédacteurs en Chef adjoints** : DAMA Mariam Myriam  
NAREALice

**Comité scientifique**

1. Pr SAWADOGO Mahamoudou, Professeur titulaire, Génétique, Université Ouaga I, Pr Joseph KI-ZERBO, Burkina Faso
2. Pr BOUSSIM I. Joseph, Professeur titulaire, Biologie et Ecologie végétales, Université Ouaga I, Pr Joseph KI-ZERBO, Burkina Faso
3. Dr SEREME Paco, Directeur de Recherche, Phytopathologie, INERA, Burkina Faso
4. Dr LOMPO François, Directeur de Recherche, Agronomie/Science du Sol, INERA, Burkina Faso
5. Dr TAMBOURA H. Hamidou, Directeur de Recherche, Génétique animale, INERA, Burkina Faso
6. Pr KONE Daouda, Professeur titulaire, Science des Sols et des Plantes, Université Félix Houphouët- Boigny, Abidjan, Côte d'Ivoire
7. Pr BIELDERS Charles, Professeur titulaire, Science des sols, Université Catholique de Louvain-la- Neuve, Belgique
8. Dr BRUGIDOU Christophe, Directeur de recherche, Inter action Plantes-Parasites, Institut de Recherche pour de Développement, Montpellier, France
9. Pr LEBEAU Frédéric, Professeur titulaire, Machinisme agricole, Université de Liège, Gembloux Agro-Biotech



10. Dr. SEREME Abdoulaye, Maître de recherche, Agronomie/Botanique, IRSAT, Burkina Faso
11. Dr. KONATE Yacouba, Maître de Conférences, Assainissement, 2iE, Burkina Faso
12. Dr PARKOUDA Charles, Maître de Recherche, Science des aliments/Biochimie, Burkina Faso
13. Dr OUATTARA/SONGRE Laurencia, Maître de recherche, Nutrition/Science des aliments, Burkina Faso
14. Pr. SISSOKO Grégoire, Professeur titulaire, Physique/Energétique, Université Cheick Anta Diop, Sénégal
15. Pr. OUATTARA Frédéric, Professeur titulaire, Géophysique, UNZ, Burkina Faso

### **Comité de lecture**

1. Dr ZIDA Elizabeth, Maître de Recherche, Phytopathologie, INERA, Burkina Faso
2. Dr BATIONO B. André, Maître de Recherche, Agroforesterie, INERA, Burkina Faso
3. Dr KIEMA André, Maître de Recherche, Pastoralisme, INERA, Burkina Faso
4. Dr ADJANOHOUN Adolphe, Directeur de recherche, Agropédologie, INRAB, Bénin
5. Dr BOUKAR Ousmane, Maître de Recherche, Génétique végétale, IITA, Kano, Nigéria
6. Dr MENSAH G. Appolinaire, Directeur de Recherche, Production animale, INRAB, Bénin
7. Dr DRAME-YAYE Aissétou, Maître de Conférences, Agroforesterie, Université Abdou Moumouni, Niger
8. Pr IPOU-IPOU Joseph, Professeur, Malherbologie, Université Félix Houphouët-Boigny, Côte d'Ivoire
9. Dr COMPAORE Emmanuel, Maître de Recherche, Agrochimie, INERA, Burkina Faso
10. Dr BA Malick, Maître de Recherche, Entomologie, INERA, Burkina Faso
11. Dr TRAORE Oumar, Directeur de Recherche, Virologie-Biotechnologie, INERA, Burkina Faso
12. Dr SAWADOGO Louis, Directeur de Recherche, Sylvopastoralisme, INERA, Burkina Faso
13. Dr ZAGRE M'Bi Bertin, Maître de Recherche, Génétique végétale, INERA, Burkina Faso
14. Dr TRAORE Amadou, Directeur de Recherche, Génétique animale, INERA, Burkina Faso
15. Dr THIOMBIANO Adjima, Professeur titulaire, Botanique/Ecologie végétale, Université Ouaga 2, Burkina Faso
16. Dr YE Siédouba Georges, Maître de Recherche, Conception machinisme agricole, IRSAT, Burkina Faso
17. Dr KAMBIRE Fabékouré Cedric, Chargée de recherche, Agro pédologie, IRSAT, Burkina Faso
18. Dr KABORE Donatien, Maître de recherche, Microbiologie/Biochimie, IRSAT, Burkina Faso
19. Dr BA/FATOUMATA Hama, Maître de recherche, Nutrition/Sciences des aliments IRSAT, Burkina Faso
20. Dr SANOGO Oumar, Maître de recherche, Physique, IRSAT, Burkina Faso
21. Dr DIANDA Boureima, Chargé de recherche, Physique, IRSAT, Burkina Faso
22. Dr OUÉDRAOGO Issaka, Maître de recherche, Physique, IRSAT, Burkina Faso
23. Dr DIALLO/KONE Martine, Maître de recherche, Chimie, IRSAT, Burkina Faso
24. Dr BONKOUNGOU Isidore, Maître assistant, Biologie, IRSAT, Burkina Faso
25. Dr SAVADOGO Salfo, Chargé de recherche, Biologie et Ecologie végétales, IRSAT, Burkina Faso
26. Pr LY Ibrahima, Professeur Titulaire, Physique/Energétique, ESP Thiès, Sénégal
27. Pr PADONOU Wilfrid, Professeur Titulaire, Biochimie, Université d'Agriculture de Kétou, Bénin
28. Dr DAKO Enock G. Achigan, Maître de conférences, Génétique et Sélection des plantes, Université Abomey Calavi, Bénin
29. Pr AMEYAPOH Yaovi, Professeur Titulaire, Microbiologie/Biochimie, Université de Lomé, Togo
30. Pr AZOUMA Yaovi Ouezou, Professeur Titulaire, Conception machinisme agricole, Université de Lomé, Togo

**Abonnement - Distribution**

DIST/DGA-V/CNRST, 03 B.P. 7047 Ouagadougou 03

**Rédaction et administration**

- Comité de rédaction, INERA 03 B.P. 8645 Ouagadougou 03 Burkina Faso ; Tél : (00226) 25 34 02 70/

25 34 71 12 ; Fax : (226) 25 34 02 71 ; Email : inera.direction@fasonet.bf

- Comité de rédaction, IRSAT 03 B.P. 7047 Ouagadougou 03 Burkina Faso ; Tél : (226) 25 35 60 31 ;

Fax : (226) 25 35 70 29 ; Email : dirsat@fasonet.bf ; Site web : www.irsat-burkina-net

**Mise en page :** ILBOUDO W. Alassane, Infographe, Presses Universitaires

**Impression :** Presses Universitaires

*Numéro tiré à 50 exemplaires.*



## SOMMAIRE

**Ismael BIO, Idrissa SOUMANA, Idi Saidou SANI, Abdou LAOUALI, Habou RABIOU, Ali MAHAMANE**

Morphometric characters and pods production of *Vachellia tortilis* subsp. raddiana (Savi) according to toposequence in the department of Goure (Niger)..11

**Souleymane SANOGO, Drissa TRAORE, BiramaT.OGOLA, Bréhima BENGALY, Mahamadou COULIBALY, Drissa OUATTARA<sup>1</sup>, Bréhima COULIBALY, Babou BA, Siaka DIALLO, Nouhoum ONGOIBA**

Aspects épidémiologiques du cancer de l'estomac au CHU Point g de Bamako (Mali).....29

**Patricia SOUBEIGA, Magloire BOUNGOU, Yamba SINARE, Noel Gabiliga THIOMBIANO, Gustave B. KABRE**

Cestodes des amphibiens de la province du Ganzourgou, Burkina Faso.....43

**Arahama TRAORE, Souleymane OUEDRAOGO**

Caractérisation des systèmes de production utilisant les bonnes pratiques d'adaptation aux changements climatiques dans le Nord du Burkina Faso.....57

**Mah Alima Esther TRAORE, Palpougouini LOMPO, Marc Christian TAHITA, Halidou TINTO, Jan JABOBS**

Prévalence et résistance aux antimicrobiens des salmonelles isolés dans la viande des animaux abattus à Nanoro (Burkina Faso).....75

**Sanouon Frédéric DABIRE, Delphine OUATTARA, Souleymane NACRO**

Ecologie des insectes foreurs de tige du riz dans l'Ouest du Burkina Faso.....91

**Adama OUEDRAOGO, Laurence RICHARD, Prisca LEBEAU, Franck STURTZ, Jean-Michel VALLAT, Benoît FUNALOT, Balé BAYALA**

Self-delivery siRNA as a versatile tool to study molecular effectors of myelin maintenance in vivo.....115

**OUEDRAOGO Rayagnéwendé Adèle, POODA Lamine, KAMBIRE Fabèkourè Cédric, KONE Martine**

Risques de pollution environnementale par l'utilisation des pesticides en maraîchage : cas des exploitations de Sakaby et de Dogona à Bobo-Dioulasso..131

**Windpouiré Vianney TARPAGA, Cheick Omar TRAORÉ, Wendkouni Lucie NANA, Albert ROUAMBA**

Evaluation agro-morphologique d'accessions d'oignon (*Allium cepa* L.) du Burkina Faso.....149

**Julien NIKIEMA, Anja BRETZLER, Suzanne YAMEOGO, Abdoul Azize BARRY, Richard SANOU, Mario SCHIRMER**

Variation spatiale et saisonnière de la qualité physico-chimique et des ions majeurs des eaux souterraines dans les granitoïdes de la zone de Tiébélé (extrême sud, Burkina Faso).....169

**Daouda GUEBRE, Salifou TRAORE, Mamoudou TRAORE, Boussa Tockville MARE, Edmond HIEN**

Conservation des sols en zone soudano-sahélienne : quelle est l'efficience des amendements ligneux ? .....199

# Self-delivery siRNA as a versatile tool to study molecular effectors of myelin maintenance *in vivo*

---

Adama OUEDRAOGO<sup>1\*</sup>, Laurence RICHARD<sup>2</sup>,  
Prisca LEBEAU<sup>2</sup>, Franck STURTZ<sup>2,4</sup>,  
Jean-Michel VALLAT<sup>2,3</sup>, Benoît FUNALOT<sup>2,3,4</sup>,  
Balé BAYALA<sup>1</sup>

## Abstract

The myelination in Schwann cells that occurs during the foetal life is governed by several transcription factors, including Egr2 gene. Unfortunately, mutations affecting this gene result in various human hereditary peripheral neuropathies, such as the Charcot-Marie-Tooth disease. There are few informations on myelin maintenance that is a dynamic process which is under the control of various genes. We have developed a technique to identify genes in peripheral myelin maintenance, using small interfering ribonucleic acids (siRNAs) to induce extinction of target genes *in vivo*. Modified self-delivery siRNAs were used to induce extinction of candidate genes without using transfection reagents. These siRNAs were injected into the sciatic nerves of adult rats. We showed that control non-targeting siRNAs did not induce significant demyelination after direct injection into sciatic nerves. The injection of anti-Egr2 siRNAs into the sciatic nerves of adult rats induced a significant and rapid demyelination, as shown by the loss of Myelin Protein Zero expression in the injected area on immunohistochemistry experiments (optic microscopy) and by direct evidence of demyelination on epon-embedded transversal sections of sciatic nerves (optic and electron microscopy). These results confirm previous research findings involving Egr2 in active myelin maintenance. Injections of anti-Dicer siRNAs similarly induced sciatic nerve demyelination, establishing that Dicer expression in adult peripheral nerves is necessary for proper myelin maintenance. This paper also reports on an original method for the use of self-delivery siRNAs to study the molecular mechanisms of myelin maintenance *in vivo*.

**Key words:** siRNA, sciatic nerves, myelin.

---

<sup>1</sup> Laboratory of animal physiology, Joseph KI-ZERBO University, Ouagadougou, Burkina Faso;

<sup>2</sup> EA 6309, School of Medicine, University of Limoges, Limoges, France;

<sup>3</sup> National Referral Center for Rare Peripheral Neuropathies and Department of Neurology, University hospital, Limoges.

<sup>4</sup> Department of Biochemistry and Molecular Genetics, University Hospital, Limoges, France.

\* Corresponding author: [ouedraogoadams2000@gmail.com](mailto:ouedraogoadams2000@gmail.com)

# Les siRNA auto-délivrés : des outils polyvalents pour l'étude *in vivo* des effecteurs moléculaires de la maintenance myélinique

## Résumé

La myélinisation dans les cellules de Schwann se produit au cours de la vie fœtale et est régie par plusieurs facteurs de transcription, y compris le gène EGR2. Malheureusement, les mutations affectant ce gène entraînent diverses neuropathies périphériques héréditaires humaines, comme la maladie de Charcot-Marie-Tooth. Il y a peu d'informations sur la maintenance de la myéline qui est un processus dynamique contrôlé par différents gènes. Nous avons développé une technique pour identifier les gènes impliqués dans le maintien de la myéline périphérique, en utilisant de petits acides ribonucléiques interférents (siRNA), dans le but d'induire l'extinction de gènes cibles *in vivo*. Des siRNA modifiés pour permettre leur auto-délivrance ont été utilisés pour induire l'extinction de gènes candidats sans utiliser de réactifs de transfection. Ces siRNA ont été injectés dans les nerfs sciatiques de rats adultes. Nous avons tout d'abord montré que les siRNA non ciblés témoins n'induisaient pas de démyélinisation significative après injection directe dans les nerfs sciatiques. L'injection de siRNA anti-Egr2 dans les nerfs sciatiques de rats adultes a induit une démyélinisation significative et rapide, comme le montre la perte d'expression de Myelin Protein Zero dans la zone injectée sur des expériences d'immunohistochimie (microscopie optique) et par la preuve directe de la démyélinisation sur coupes transversales incluses en Epon des nerfs sciatiques (microscopie optique et électronique). Ces résultats confirment les résultats de recherches antérieures impliquant Egr2 dans la maintenance active de la myéline. Des injections de siRNA anti-Dicer induisent de la même manière une démyélinisation du nerf sciatique, établissant que l'expression de Dicer dans les nerfs périphériques adultes est nécessaire pour une bonne maintenance de la myéline. Cet article présente également une méthode originale d'utilisation des siRNA auto-administrés pour étudier les mécanismes moléculaires de la maintenance de la myéline *in vivo*.

**Mots clés :** siRNA, nerfs sciatiques, myéline.

## Introduction

The higher vertebrate nervous system is characterized by the coexistence of neurons and glial cells. Schwann cells are responsible for producing myelin that is wrapped around axons in the peripheral nerves. The myelin serves as an insulator to facilitate signal propagation along axons. The transcription factor Egr2/Krox20 is a prime regulator of Schwann cells myelination, nerves from Egr2- knockout mice being hypomyelinated and populated with Schwann cells that fail to exit the cell cycle (Topilko et al., 1994). In patients with congenital hypomyelinating neuropathy, Charcot-Marie-Tooth disease or Dejerine-Sottas syndrome; mutations in EGR2 are found (Warneret al., 1998; Timmerman et al., 1999). Many molecular effectors of peripheral nerve myelination

have been identified during the last two decades (Woodhoo et al., 2009). *Egr2* is permanently expressed in myelinating schwann cells and downregulated after axonal injury, which results in the elimination of myelin sheath (Ghislain et Charnay, 2006). This raised the possibility that *Egr2* expression might be required for myelin maintenance. Specific inactivation of *Egr2* in adult mouse sciatic nerve by inducible knockout experiments resulted in severe demyelination, involving rapid Schwann cells dedifferentiation and increased proliferation, followed by an attempt to remyelinate and a block at the promyelinating stage. These data established that *Egr2* is not only required for the onset of myelination but that it is also crucial for the maintenance of the myelinating state (Decker et al., 2006).

Apart from this study using conditional knockout mice, very little knowledge is available on genes and mechanisms responsible for maintenance of peripheral myelin (Canu et al., 2009, Bremer et al., 2011).

We have developed a new technique to identify genes involved in peripheral myelin maintenance, using small interfering RNAs (siRNAs) which have the ability to silence target genes *in vivo*. For this purpose, we used “self-delivery” siRNAs (Accell siRNA, Dharmacon) to silence candidate genes without using transfection reagents. These modified siRNAs were previously shown to be able to down-regulate target genes *in vivo* after direct injection into the skin (Gonzalez-Gonzalez et al., 2010, Lara et al., 2012).

Another siRNA targeting *KLF6-SV1* was shown to inhibit ovarian cancer development after intraperitoneal injection (DiFeo et al., 2009). In our study, anti-*Egr2* and anti-Dicer siRNAs were used in sciatic nerves of adult rats (direct injection of siRNAs, *in vivo* model). This allowed us to confirm the involvement of *EGR2* in peripheral myelin maintenance *in vivo*, and to show that the miRNA-processing protein Dicer (which was recently shown to be involved in peripheral nerve myelination (Pereira et al., 2010) is also involved in the myelin maintenance in adult rat sciatic nerves.

## **1. Materials and methods**

### **1.1. Animals**

For *in vivo* study of myelin maintenance and injection of siRNAs, we used adult male Sprague-Dawley rats between 10 and 12 weeks of age. All rats were obtained from DEPRE breeding center, Saint-Doulchard, France.

There were two animals housed per cage, in a temperature and humidity-controlled room with 12:12 h light/dark cycle. The animals were fed with standard chow and water *ad libitum*.

Adequate measures were taken to minimize pain and discomfort. The animals were housed for a minimum duration of one week before being subjected to the experiments. All procedures were performed with the approval of the animal ethics committee of the University of Limoges (authorization number 15-2013-15).

## **1.2. *In vivo* injection of siRNA in the rat sciatic nerve**

Rats were deeply anesthetized by inhalation of isoflurane mixed to O<sub>2</sub>. All surgical techniques were done under aseptic conditions and performed using a standard dissecting microscope. After anesthesia, the hind legs were attached; the sciatic nerve was exposed unilaterally after skin and muscle incision. The injection point was located above the bifurcation of the nerve in the mono fascicular part of the sciatic nerve. Injections were performed under a dissection microscope, using a manually controlled micro-syringe (see supplementary figure 1). The needle was inserted across the perineurium, then the selected volume of siRNA diluted in isotonic NaCl was slowly injected into the nerve (in the endoneurium). After injection, a mark was made with a non-resorbable suture fixed at the level of the injection point, on the lateral muscle. The muscle and skin were closed with some staples. The rats were returned to their cages and regained mobility. At various times after injection, the rats were again anesthetized in order to remove the sciatic nerve, then sacrificed by intra-cardiac injection of ketamine (0.5 ml at 10 mg/ml; PANPHARMA). A rather large fragment of the sciatic nerve (approximately 1 cm-long) was removed in order to have oth parts of the nerve above and below the injection point. For each time and each siRNA pool (non-targeting siRNAs and anti-Egr2 siRNAs), we obtained three formalin-fixed paraffin-embedded sciatic nerves and three glutaraldehyde-fixed epon-embedded nerves.



Supplementary figure 1: Injection of siRNAs in the endoneurium of an adult rat sciatic nerve using a micro-syringe.

**Tables:**

**Table 1. Oligonucleotide primers used for RT-qPCR**

**Gapdh**

Forward primer TGCACCACCAACTGCTTAG

Reverse primer GGATGCAGGGATGATGTT

**Hprt**

Forward primer CTCATGGACTGATTATGGACAGGAC

Reverse primer GCAGGTCAGCAAAGAACTTATAGCC

**Egr2**

Forward primer CAGTACCCTGGTGCCAGCTG

Reverse primer TGTGGATCTCTCTGGCACGG

**Dicer**

Forward primer GAGTCTCTTGCTGGTGCCAT

Reverse primer CGCCTGTGAGTCTGGAAGC

**Table2. Self-delivery siRNA nucleotide sequences**

**Dicer**

Sequence 1 5'CCCCUAUCGUGAAAUAUG 3'(13546.4 g/mol)

Sequence 2 5'CCAGGAUCCACAAAACGAA 3' (13514.0 g/mol)

Sequence 3 5'UGAUCAGCCUCAUCGAUUU 3' (13572.2 g/mol)

Sequence 4 5'GUCUGAAGCUCGUUAUAGGC 3' (13566.6 g/mol)

## **Egr2**

Sequence 1 5'CCAGAAGGCAUCAUCAUA 3' (13510.8 g/mol)

Sequence 2 5'CUGACUUGUUUGGUUAUUA 3' (13546.3 g/mol)

Sequence 3 5' GGUUUAAGUAUGGCUGUAU 3' (13535.2 g/mol)

Sequence 4 5' CCAGUAACUCUCAGUGGUU 3' (13561.4 g/mol)

### **1.3. Fixation and inclusion of sciatic nerves**

For the immunohistochemical study of the nerve, nerve fragments were fixed in formalin and included in paraffin. Five micrometer-thick sections were performed using a Leica microtome. Dewaxing was done through two baths in toluene and two others in absolute alcohol. The rehydration was performed using a water bath for 10 min.

For the semi-thin and ultrastructural analysis of sciatic nerves, samples were fixed in 2.5% glutaraldéhyde diluted in cacodylate buffer, postfixed in 1% osmic acid, dehydrated in successive acetone baths and included in epoxy resin. Dehydration was obtained by increasing concentrations of acetone diluted in H<sub>2</sub>O and inclusion was carried out in epoxy resin. Semi-thin transverse sections were performed using an ultramicrotome, mounted on glass slides and stained with toluidine blue. An ultrastructural study was performed on ultrathin sections (60-100 nm), after staining with acetate uranyl and lead citrate, using an electron microscope (JEOL 1011).

### **1.4. Immunohistochemistry of sciatic nerves**

Unmasking of antigenic sites on rehydrated sections was performed at 98°C for 25 min in retrieval solution (Dako). The slides were then rinsed with water. 100 µl of peroxydase blocking solution was placed on the slide for 5 min and then rinsed with water and PBS. 100 µl of goat serum was placed on each slide for 30 min and then 100 µl of primary antibodies.


The slides were incubated overnight at 4°C, then rinsed in PBS. The revelation was made using 100 µl of biotinylated secondary antibodies (vectastain diluted biotinylated antibody, VECTOR) for 30 min. The slides were again rinsed with PBS. Vectastain elite ABC kit was added to each slide for 30 min, then 100 µl of 3, 3'-diaminobenzidine was added. H<sub>2</sub>O<sub>2</sub> was added, the slides were rinsed with water and placed for 15 s in hematoxylin, rinsed again in water, then in ammonia water and finally in water. Two

baths of absolute alcohol and two others of toluene were realized, and the cuts were mounted between slide and coverslip in a non-aqueous mounting medium.

## 2. Results

### 2.1. Effect of siRNAs targeting Egr2 on myelin maintenance *in vivo*

Sciatic nerves were injected with anti-Egr2 and non-targeting siRNA using 30µl at 1µM of each pool. We studied the temporal pattern of demyelination by examining serial longitudinal sections of sciatic nerves removed at various times (1 day, 3 days, 5 days, one week) after injection. In the immunohistochemistry experiments, acute demyelination manifested as a loss of Myelin Protein Zero (P0) staining, associated with invasion by macrophages (CD68- positives cells). There was no visible loss of P0 staining and no invasion by macrophages in nerves treated by non-targeting siRNAs at any time point. In the sciatic nerve that had received anti-Egr2 siRNAs, a focal demyelination (corresponding to the injected area) was observed on samples taken 3 days, 5 days and one week after injection (fig 1). No demyelination was observed in nerves taken 1 day after injection. P0-negative areas were smaller in nerves taken 3 days after injection and larger in the nerves taken at 5 days and one week (Fig. 1B-D). In addition, anti-CD68 immunostaining showed an absence of CD68 staining at 1 day and presence of an increasing number of macrophages at 3 days, 5 days and one week (Fig. 1E-G). On semi-thin (light microscopy) and ultra-thin (electron microscopy) transverse sections, marked acute demyelination was visible for the samples taken 5 days and one week after injection of anti-Egr2 siRNA. The semi-thin sections showed demyelination in nerves treated with siRNAs targeting Egr2 but no or very slight demyelination in nerves treated with nontargeting siRNAs (Fig 2A-C). Ultrastructural analysis showed a marked acute and focal demyelination after treatment with anti-Egr2 siRNAs, which was absent from the nerves treated with control siRNAs (Figure 3A-B).



**Figure 1.** Immunohistochemistry of Myelin Protein Zero (P0) and CD68 in rat sciatic nerves injected with anti-Egr2 and control non-targeting siRNAs.

**A.** P0 staining of a sciatic nerve injected with control siRNA, showing a homogeneous staining of myelin sheaths with no areas of demyelination (5 days after injection).


**B.** 3 days after injection of anti-Egr2 siRNAs, presence of a demyelinated area of limited size (lack of brown P0 staining, arrows).

**C.** Five days after injection of anti-Egr2 siRNAs, presence of a larger area of demyelination (arrows).


**D.** One day after injection of anti-Egr2 siRNAs, absence of CD68 staining, indicating an absence of macrophages in the injected nerve.

**E.** 3 days after injection of anti-Egr2 siRNAs (same nerve as in panel B), presence of CD68-positive macrophages in the demyelinated area.

**F.** 5 days after injection of anti-Egr2 siRNAs (same nerve as in panel C), presence of a higher number of CD68-positive macrophages in the large area of demyelination.



**Figure 2:** Semi-thin sections of adult rat sciatic nerves five days after injection of siRNAs. Injection of 30 µL of non-targeting siRNAs resulted in either no effect (A, absence of demyelination) or in a slight localized demyelination (B, arrows). Injection of 30 µL of anti Egr2 siRNAs results in a marked area of demyelination (C, arrows).



**Figure 3 :** Ultrastructural study of nerves injected with anti-Egr2 siRNAs.


**A.** After five days of treatment with anti-Egr2 siRNAs, presence of various types of demyelinating features within the lesion: myelinated fiber with a near-normal appearance (white arrowhead), actively demyelinating fiber (white arrow) and macrophages, loaded with myelin debris (black arrows).

**B.** five days after injection of anti-Egr2 siRNAs, several large axons appear as demyelinated (absence of myelin sheaths, black arrows), whereas a few other still remain myelinated (white arrows).

**C.** (detail of panel B): presence of a macrophage loaded with myelin debris immediately adjacent to a demyelinated axon.

## 2.2. Effect of siRNAs targeting Dicer on gene expression and myelin maintenance

Injection of anti-Dicer siRNAs in rat sciatic nerves resulted in active demyelination, as shown by semi-thin (Fig. 4B) and ultra-thin (Fig. 4C-D) sections, 5 days after treatment. Patterns of demyelination were not significantly different from those observed with anti-Egr2 siRNAs. These last results demonstrate that expression of Dicer is necessary for peripheral myelin maintenance in adult rat sciatic nerves.



**Figure 4 :** Effect of siRNAs targeting Dicer on gene expression and myelin maintenance.

**A.** Treatment of DRG neuron-Schwann cell co-cultures with anti-Dicer siRNAs results in a 72% decrease of Dicer mRNA.

**B.** On the semi-thin transverse section of a sciatic nerve 5 days after injection of anti-Dicer siRNAs, presence of a large area of demyelination.

**C-D:** Ultra-thin sections after injection of anti-Dicer siRNAs. Five days after injection of anti-Dicer siRNAs, presence of many large demyelinated (nude) axons (black arrows), together with macrophages loaded with myelin debris (white arrows).

### 3. Discussion

In the peripheral nerve, *Egr2* is expressed in myelinating Schwann cells but remains expressed at high levels throughout life, which led to the hypothesis that *Egr2* could also be involved in peripheral myelin maintenance. In experiments using inducible knockout of the *Egr2* gene in mouse sciatic nerves (Cre-Lox excision of the *Egr2* gene using estrogen receptor-induced Cre expression), Decker et al., showed that focal excision of the *Egr2* gene after injection of hydroxytamoxifen resulted in active demyelination in the injected area (Decker et al., 2006). This suggested that *Egr2* constant expression in the peripheral nervous system is required for peripheral myelin maintenance. In the absence of *Egr2* gene expression, a specific program of dedifferentiation would be engaged, leading to active myelin destruction. One possible mechanism for this active demyelination would be the reactivation of *Egr2*-silenced genes involved in maintaining the immature stage of Schwann cells (Decker et al., 2006).

We took advantage of self-delivery siRNAs to perform an *in situ* silencing of *Egr2* mRNA in rat sciatic nerve without affecting the *Egr2* gene itself. This approach combines several advantages: it avoids the generation of a transgenic rodent model, which is expensive and time-consuming; it also allows to deliver siRNAs without any transfection reagent, which could be toxic for the nerve cells, induce reactive demyelination by itself, and relatively inefficient for the transfection of primary quiescent cells. The self-delivery siRNAs have been shown to be efficient for *in vivo* inactivation of target genes.

However, this approach had been used in a limited number of *in vivo* experiments, having been tested in skin injections to down-regulate various target genes and in intraperitoneal injections to treat an animal model of ovarian cancer ([DiFeo et al., 2009 ; Gonzalez-Gonzalez et al., 2010]). This type of approach had never been used to silence gene expression in peripheral nerves before. By this mean, we were able to confirm that *Egr2* silencing results in active demyelination in the absence of non-specific effect of the siRNAs (no significant demyelination after treatment with non-targeting siRNAs). Our results confirm by a completely different technique the findings of Decker et al. (2006) suggesting that peripheral myelin maintenance is a dynamic phenomenon requiring constant expression of *Egr2* in the peripheral nervous system.

These results also constitute a proof of concept for the use of self-delivery siRNAs to silence various genes in peripheral nerve Schwann cells *in vivo*, without the need for

transgenic animals. Another mean to down-regulate specific mRNAs in peripheral nerves could have been to use small hairpin RNA (shRNAs) plasmids delivered by lentiviral particles into the peripheral nerves. We did not test this approach because it was previously shown that in adult nerves, lentiviral vectors were not efficient, as very few cells were infected (Özcelik et al., 2010). The siRNA induced demyelination we performed could also constitute a clever model of peripheral nerve demyelination, because chemically-induced PNS demyelination also results in significant axonal injury because of non-specific toxic effect of the chemical agents (as is the case with lysophosphatidyl-choline).

After showing that anti-Dicer siRNAs are able to down-regulate the target mRNA in cell cultures, we injected the siRNAs in rat sciatic nerves, which resulted here again in active demyelination. By contrast with *Egr2*, which is only expressed by Schwann cells in the peripheral nervous system, we cannot rule out that anti-Dicer siRNAs could also target Dicer in neurons, which could indirectly contribute to the observed demyelination through perturbed axon-Schwann cell interactions. Whatever the case, our results show that constant expression of Dicer in the peripheral nerves is necessary for peripheral myelin maintenance.

This suggests that this process is (at least in part) controlled by specific miRNAs, which could down-regulate genes associated with the immature stage of Schwann cells.

To conclude, constant expression of *Egr2* is essential for peripheral myelin maintenance and Dicer expression is necessary for adult rat sciatic nerves myelin maintenance. Experimental studies are necessary to determine which miRNAs are involved in the regulation of this dynamic phenomenon.

## Bibliographic References

Bremer J, Baumann F, Tiberi C, Wessig C, Fischer H, Schwarz P, Steele AD, Toyka KV, Nave KA, Weis J, Aguzzi A (2010) Axonal prion protein is required for peripheral myelin maintenance. *Nat Neurosci* 13: 310–318.

Bremer J, O'Connor T, Tiberi C, Rehrauer H, Weis J, Aguzzi A (2010) Ablation of Dicer from Murine Schwann Cells Increases Their Proliferation while Blocking Myelination. *PLoS One* 5: e12450.

Bremer M, Fröb F, Kichko T, Reeh P, Tamm ER, Suter U, Wegner M (2011) Sox10 is required for Schwann-cell homeostasis and myelin maintenance in the adult peripheral nerve. *Glia* 59: 1022–1032.

Canu MH, Carnaud M, Picquet F, Goutebroze L (2009) Activity-dependent regulation of myelin maintenance in the adult rat. *Brain Res* 1252: 45–51.

Decker L, Desmarquet-Trin-Dinh C, Taillebourg E, Ghislain J, Vallat JM, Charnay P (2006). Peripheral Myelin Maintenance Is a Dynamic process Requiring Constant Krox20 Expression. *J Neurosci* 26: 9771–9779.

DiFeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G and Martignetti JA. (2009) KLF6-SV1 Is a Novel Antiapoptotic Protein That Targets the BH3- Only Protein NOXA for Degradation and Whose Inhibition Extends Survival in an Ovarian Cancer Model *Cancer Res* 69: 4733-4741.

Ghislain J, Charnay P (2006) Control of myelination in Schwann cells: a Krox20 cis regulatory element integrates Oct6, Brn2 and Sox10 activities. *EMBO Rep* 7: 52–58.

Gonzalez-Gonzalez E, Speaker TJ, Hickerson RP, Spitler R, Flores MA, Leake D, Contag CH and Kaspar RL (2010) Silencing of Reporter Gene Expression in Skin Using siRNAs and Expression of Plasmid DNA Delivered by a Soluble Protrusion Array Device (PAD) *Mol Ther* 18: 1667–1674.

Hickerson RP, Flores MA, Leake D, Lara MF, Contag CH, Leachman SA and Kaspar RL (2011) Use of Self-Delivery siRNAs to Inhibit Gene Expression in an Organotypic Pachyonychia Congenita. *J Invest Dermatol* 131: 1037–1044.

Lara MF, Gonzalez-Gonzalez E, Speaker TJ, Hickerson RP, Leake D, Milstone LM, Contag CH, and Kaspar RL (2012) Inhibition of CD44 Gene Expression in Human Skin

Models, Using Self-Delivery Short Interfering RNA Administered by Dissolvable Microneedle Arrays. *Hum Gene Ther* 23: 816–823.

Livak KJ and Schmittgen TD (2001) Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2DDCT Method. *Methods* 25: 402–408.

Murphy P, Topilko P, Schneider-Maunoury S, Seitanidou T, Baron-Van Evercooren A, Charnay P (1996) The regulation of Krox-20 expression reveals important steps in the control of peripheral glial cell development. *Development* 122:2847–2857.

Özcelik M, Cotter L, Jacob C, Pereira JA, Relvas J, Suter U, and Tricaud N (2010) Pals1 Is a Major Regulator of the Epithelial-Like Polarization and the Extension of the Myelin Sheath in Peripheral Nerves. *J Neurosci* 30:4120–4131.

Pereira JA, Baumann R, Norrmén C, Somandin C, Mieke M, Jacob C, Lüthmann T, Hall-Bozic H, Mantei N, Meijer D, Suter U. (2010) Dicer in Schwann cells is required for myelination and axonal integrity. *J Neurosci* 30 : 6763-6775.

Svenningsen A.F, Shan W.S, Colman D.R, Pedraza L (2003) Rapid Method for Culturing Embryonic Neuron–Glial Cell Cocultures. *J Neurosci Res* 72: 565–573.

Timmerman V, De Jonghe P, Ceuterick C, De Vriendt E, Lofgren A, Nelis E, Warner LE,

Lupski JR, Martin JJ, Van Broeckhoven C (1999) Novel missense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype. *Neurology* 52: 1827–1832.

Topilko P, Levi G, Merlo G, Mantero S, Desmarquet C, Mancardi G, Charnay P (1997) Differential regulation of the zinc finger genes Krox-20 and Krox-24 (*Egr-1*) suggests antagonistic roles in Schwann cells. *J Neurosci Res* 50: 702–712.

Topilko P, Schneider-Maunoury S, Levi G, Baron-Van Evercooren A, Chennoufi AB, Seitanidou T, Babinet C, Charnay P (1994) Krox-20 controls myelination in the peripheral nervous system. *Nature* 371: 796 –799.

Verrier JD, Semple-Rowland S, Madorsky I, Papin JE, and Notterpek L (2010) Reduction of Dicer Impairs Schwann Cell Differentiation and Myelination. *J Neurosci Res* 88: 2558–2568.

Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, Koob KG, Lupski JR (1998) Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. *Nat Genet* 18: 382–384.

Woodhoo A, Alonso MB, Droggiti A, Turmaine M, D'Antonio M, Parkinson DB, Wilton DK, Al-Shawi R, Simons P, Shen J, Guillemot F, Radtke F, Meijer D, Feltri ML, Wrabetz L, Mirsky R, Jessen KR (2009) Notch controls embryonic Schwann cell differentiation, postnatal myelination and adult plasticity. *Nat Neurosci* 12: 839-847.

Yun B, Andereg A, Menichella D, Wrabetz L, Feltri ML, and Awatramani R. (2010) MicroRNA-Deficient Schwann Cells Display Congenital Hypomyelination. *J Neurosci* 30: 7722–7728.